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UNIVERSAL OUTPATIENT IMMUNOTHERAPEUTIC APPROACH FOR 
HEME MALIGNANCIES IN THE ABSENCE OF DONOR CHIMERISM: 
ANTI-TUMOR RESPONSES IN HLA-HAPLOIDENTICAL CELL INFUSIONS 
IN IOOCGY TREATED HOSTS 
Co/via, G.Ad; Lambert, id; Lmn, L.Gd, Rathore, Rd; Falvev, M.Td; 
Abedi, Md; Quesenberry, p.jd; Elfenbein, G.J. ~ 1. Adele R Decof 
Cancer Center, Roger Williams Medical Center, Providence, RI; 
2. DivisioTz of Hematology, University Hospital of GeTzeva, Geneva, 
Switzerland. 
Previously, we studied cellular immunotherapy with HLA-identi- 
cal sibling donors using 100cGy conditioning and infusing lxl08 
CD3+ cells/kg from non-mobilized peripheral blood. An impres- 
sive complete response (CR) rate was achieved in 4 of 11 patients 
(pts) with refractory hematologic malignancies (Blood 100:442, 
2002). Responding pts were transiently or permanently chimeric. 
However, only approximately 35% of pts otherwise ligible for 
allogeneic BMT have an HLA-identical sibling donor. On the 
other hand, nearly 100% of pts have HLA-haploidentical (HLA- 
H) donors, making HLA-H BMT an attractive area of investiga- 
tion. We performed 15 HLA-H peripheral blood stem cell (PBSC) 
infusions in pts with refractory heme malignancies. The CD3+ 
dose was 1-2x10 s cells/kg infused along with 2-4x106 CD34+ 
cells/kg. G-CSF (10 ug/kg for 3 days was used to mobilize PBSC. 
The transplant conditioning reghnen was 100cGy TBI on day 0. 
Median age was 55 (range 50-72). Diagnoses were: AML(4), 
CML(1), NHL(5), MDS(1) and MM(4). Donor chimerism was 
measured Q2 weeks. One treatment related death (7%) occurred 
from grade 1V AGVHD in apt  with 100% chimerism. Most pts 
had a transient febrile syndrome termed "haplo-immunostorm." 
Pts had mild pancytopenia starting 3 wks after HLA-H, most 
requiring brief transfusion support. Four nrajor clinical responses 
occurred. All of these responses were in the absence of measurable 
donor chimerism (<5%). All evaluable pts with AML and one with 
NHL achieved a CR. In summary: 1) very low dose TBI of 100cGy 
followed by HLA-H transplant is a biologically active treatment 
that eradicated far advanced isease; 2) all tumor responses 
occurred outside of detectable chimerism; 3) HLA-H with PBSCT 
is well tolerated with minimal non-hematologic to,city for the 
majority of pts; and 4) this is the first report of successful outpatient 
haploidentical inmmnotherapy achieving clinical responses for 
patients with end stage, refractory malignancies. Hypotheses con- 
cerning the mechanism ofthe biological effect include: 1) an initial 
graft vs. tumor cell kill after which donor cells are rejected, 2) an 
alteration of the host innnune response augmenting minor immu- 
nity or breaking host tumor tolerance, 3) persistent on-detectable 
micro-chimerism, or 4) a combination ofany of the three. 
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SUSTAINED ENGRAFTMENT OF HLA-MATCHED RELATED, T-CELL 
DEPLETED (TCD), PERIPHERAL BLOOD STEM CELL (PBSC)/BONE MAR- 
ROW (BM) TRANSPLANTS IN ADULTS WITH HEMATOLOGIC MALIG- 
NANCIES WITHOUT THE USE OF ANTITHYMOCYTE GLOBULIN (ATG) 
Jakz~bowski, A.A.; Castro-3/lalaspinal H.; Ke'rnmT, N.; Papadopoulos, 
E.; PeJ~ales, M.; Y0ztng, ft.; T,~omas, A.; O'Reil!y, R.J. Memorial Slom~ 
Ketterhzg CaTzcev Cen~e'~; New ~'rk, N}~ 
Acute and chronic GvHD, major causes of post-transplant mor- 
bidity and mortality, can be prevented by TCD. A limitation to 
the effectiveness of such transplants is the risk of graft 
rejection(GR)/failure(GF) caused by radioresistant, donor-reactive 
host T cells, which regenerate after transplant. Initial trials of 
TCD BM grafts from HLA matched siblings, showed a GF inci- 
dence of <14% in adults, vs.<5% for similarly matched unmodi- 
fied BM grafts. Previous work identified a conditioning regilnen 
of hyperfractionated total body irradiation (HTBI), thiotepa nd 
cyclophosphamide with ATG which reduced GF to <2%. Howev- 
er, studies of ATG recipients demonstrated delayed immune 
reconstitution, and a prolonged time 'at risk' for opportunistic 
infections.We hypothesized that high CD34+ cell doses coupled 
with HTBI,  thiotepa (51ng/kg)x2d and fludarabine 
(25mg/me2)x5d might obviate the need for ATG. Such a regimen 
has been evaluated in 22 adult transplants. PBSC and BM grafts 
were depleted o fT  cells by Isolex 300i CD34 selection + E-roset- 
ring, and SBA agglutination +E-rosetting, respectively . There 
were 13 males and 9 females, median age 46 yrs(range 19-60). 
Diseases: AML CRI(7), AML CR2(1), ALL CRI(1), biphenotypic 
acute leukemia CRI(2), CML(4), MDS-RAEBIT(2), NHL(5). 
Median follow-up: 201d(13-446). Two patients received BM and 
20 PBSC grafts. By d+30, 21 patients had an ANC)500 (1 patient 
too early (TE)), and 14 had platelets (plts) > 50k (1 TE). By 
d+100, 21 had an ANC >500 (1 TE), and 15 had >50k plts (1 TE, 
2 died early). Median time to ANC >500 for all patients was 
12d(range 10-21), and to plts >50k for 15 patients was 18d(range 
14-96). No patient developed acute (20 evaluable) or chronic (15 
evaluable) GvHD. Chimerism studies on BM at d+100 showed 
I2/I5 patients were 100%, 2/i5 were 95-98% donor (1/15 not 
evaluated). There have been no GR/GFs. Two patients with sec- 
ondary AML relapsed, one at 2 months responded to DLI, and is 
100% donor in remission at 6 months, and 1 at 10 months who 
died of complications. These results suggest that this regimen is 
sufficient o secure engraftment of HLA-matched TCD trans- 
plants without he addition of ATG. The influence of this regi- 
men on immune reconstitution is under study. 
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MALE PREDOMINANCE AMONG JAPANESE ADULT PATIENTS WITH 
LATE-ONSET HEMORRHAGIC CYSTITIS (HC) AFTER HEMATOPOIETIC 
STEM CELL TRANSPLANTATION (HSCT) 
Asano, Y.; Kanda, Y.; Ogawa, N.; Ogawa, S.; C,~iba, S.; Hh'ai, H. Depm-t- 
meat of Cell Therapy & Tram'plantation 34edicine, University of Tokyo. 
Background: Late-onset HC after HSCT is mainly caused by 
viral infections, and therefore, its incidence and risk factors may 
differ among populations. Patient and methods: We retrospective- 
ly analyzed the records of 141 Japanese adult patients who under- 
went first allogeneic HSCT from June 1995 to August 2002 at the 
University of "Tokyo Hospital. Prevention of cyclophosphamide- 
induced HC was performed with mesna and forced diuresis. HC 
was diagnosed based on macroscopic hematuria or sustained 
microhematuria with clinical symptoms de novo at least 10 days 
after HSCT. Hematuria ssociated with generalized bleeding ten- 
dency or bacteriuria was excluded. Urine samples were subjected 
to PCR and/or culture to detect viral infections. Results: Nineteen 
patients developed HC a median of 51 days (range 11-380) after 
HSCT with a 2-year cmnulative incidence of 14.2%. Adenovirus 
(AdV) was detected in the urine samples of 10 HC patients, of 
whom 8 had AdV type 1 I. Five of their 6 available serum samples 
were also positive for AdV type 11. The 3-year survival after the 
onset of HC was only 27%. Male sex and the development of
acute GVHD were identified as significant risk factors for HC by 
univariate analyses and both were shown to be independently sig- 
nificant using proportional hazard modeling with relative risks of 
7.52 (05% CI; 1.00-56.4, P=0.050) and 4.37 (95% CI; 1.65-11.6, 
P=0.0031), respectively. Conclusion: AdV type 11 infection 
appeared to play a major role in late onset HC in Japanese popula- 
tion. In addition, we identified male sex as a significant risk factor 
for HC. These findings uggested that late onset HC after HSCT 
may be caused by the reactivation of latent infection, because the 
male predominance has been already known in children with 
AdV-induced acute HC and also, its incidence was reported to be 
higher alnongJapanese children. 
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